BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33883178)

  • 1. ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma.
    Pedersen KS; Foster NR; Overman MJ; Boland PM; Kim SS; Arrambide KA; Jaszewski BL; Bekaii-Saab T; Graham RP; Welch J; Wilson RH; McWilliams RR
    Clin Cancer Res; 2021 Jul; 27(13):3641-3648. PubMed ID: 33883178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China.
    Zhang L; Wang LY; Deng YM; Wang FH; Feng F; Chen YC; An X; Chen C; Xu RH; Li YH
    J BUON; 2011; 16(4):689-96. PubMed ID: 22331723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of programmed death-ligand 1 expression and microsatellite status in small bowel adenocarcinoma.
    Klose J; Lasitschka F; Horsch C; Strowitzki MJ; Bruckner T; Volz C; Schmidt T; Schneider M
    Scand J Gastroenterol; 2020 Mar; 55(3):321-329. PubMed ID: 32191146
    [No Abstract]   [Full Text] [Related]  

  • 4. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma.
    Xiang XJ; Liu YW; Zhang L; Qiu F; Yu F; Zhan ZY; Feng M; Yan J; Zhao JG; Xiong JP
    Anticancer Drugs; 2012 Jun; 23(5):561-6. PubMed ID: 22481063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
    Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.
    Zaanan A; Costes L; Gauthier M; Malka D; Locher C; Mitry E; Tougeron D; Lecomte T; Gornet JM; Sobhani I; Moulin V; Afchain P; Taïeb J; Bonnetain F; Aparicio T
    Ann Oncol; 2010 Sep; 21(9):1786-1793. PubMed ID: 20223786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
    N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in small bowel adenocarcinoma: a potential role?
    Vitiello F; Cereda S; Foti S; Liscia N; Mazza E; Ronzoni M; Cascinu S
    Immunol Med; 2024 Mar; 47(1):1-5. PubMed ID: 37293784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
    Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L
    J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.
    Maio M; Ascierto PA; Manzyuk L; Motola-Kuba D; Penel N; Cassier PA; Bariani GM; De Jesus Acosta A; Doi T; Longo F; Miller WH; Oh DY; Gottfried M; Xu L; Jin F; Norwood K; Marabelle A
    Ann Oncol; 2022 Sep; 33(9):929-938. PubMed ID: 35680043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China.
    Yan H; Song L; Li Y; Xu Q; Guo W; Lin S; Jiang W; Wang Z; Deng L; Huang Z; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Yu J; Dong X; Gong Q; Deng J; Chen X; Wang J; Zhang G; Yang N; Zhang Y; Zeng L
    Cancer Immunol Immunother; 2024 Mar; 73(4):74. PubMed ID: 38451314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
    Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
    J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
    Bellone S; Roque DM; Siegel ER; Buza N; Hui P; Bonazzoli E; Guglielmi A; Zammataro L; Nagarkatti N; Zaidi S; Lee J; Silasi DA; Huang GS; Andikyan V; Damast S; Clark M; Azodi M; Schwartz PE; Tymon-Rosario JR; Harold JA; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Alexandrov LB; Iwasaki A; Kong Y; Song E; Dong W; Elvin JA; Choi J; Santin AD
    Cancer; 2022 Mar; 128(6):1206-1218. PubMed ID: 34875107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy for small bowel adenocarcinoma after curative surgery.
    Koo DH; Yun SC; Hong YS; Ryu MH; Lee JL; Chang HM; Kang YK; Kim SC; Han DJ; Lee YJ; Kim TW
    Oncology; 2011; 80(3-4):208-13. PubMed ID: 21720183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
    Maubec E; Boubaya M; Petrow P; Beylot-Barry M; Basset-Seguin N; Deschamps L; Grob JJ; Dréno B; Scheer-Senyarich I; Bloch-Queyrat C; Leccia MT; Stefan A; Saiag P; Grange F; Meyer N; de Quatrebarbes J; Dinulescu M; Legoupil D; Machet L; Dereure O; Zehou O; Montaudié H; Wierzbicka-Hainaut E; Le Corre Y; Mansard S; Guégan S; Arnault JP; Dalac S; Aubin F; Alloux C; Lopez I; Cherbal S; Tibi A; Lévy V;
    J Clin Oncol; 2020 Sep; 38(26):3051-3061. PubMed ID: 32730186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant immunotherapy in microsatellite instability-high (MSI-H) duodenal adenocarcinoma leads to pathological complete response and paves the way for new strategies.
    Ziane Bouziane S; Mans L; Bucalau AM; Demetter P; Pezzullo M; Andre C; Loi P; Navez J; Marcelis L; Puleo F; Charette N; Closset J; Van Laethem JL
    Eur J Cancer; 2024 Jul; 206():114128. PubMed ID: 38805957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in incidence, treatment and survival of small bowel adenocarcinomas between 1999 and 2013: a population-based study in The Netherlands.
    Legué LM; Bernards N; Gerritse SL; van Oudheusden TR; de Hingh IH; Creemers GM; Ten Tije AJ; Lemmens VE
    Acta Oncol; 2016; 55(9-10):1183-1189. PubMed ID: 27170100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapeutic management of small bowel adenocarcinoma associated with Crohn's disease.
    Bruckner HW; Hrehorovich VR; Sawhney HS; Meeus SI; Coopeman AM
    J Chemother; 2006 Oct; 18(5):545-8. PubMed ID: 17127233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
    JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.
    Hansen AR; Massard C; Ott PA; Haas NB; Lopez JS; Ejadi S; Wallmark JM; Keam B; Delord JP; Aggarwal R; Gould M; Yang P; Keefe SM; Piha-Paul SA
    Ann Oncol; 2018 Aug; 29(8):1807-1813. PubMed ID: 29992241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.